Enzene Biosciences Uveils ranibizumab To Treat Neovascular AMD

Following the approval of bevacizumab for the treatment of metastatic colorectal cancer, Pune-based Enzene Biosciences has now launched ranibizumab, a biosimilar of the originator medication Lucentis, which is sold in India under the brand name Accentrix.

A recombinant Fab that is used as a therapy for neovascular age-related macular degeneration (AMD), the ranibizumab biosimilar is the company’s 7th biosimilar and could significantly lower treatment costs for thousands of Indian patients, as per pharmabiz. 

Enzene's ranibizumab biosimilar demonstrated comparable clinical effectiveness with Lucentis in phase 3 clinical tests and is manufactured in the company's Chakan, Pune, factory using the company's cutting-edge MAR system.

Speaking on the launch of its 7th biosimilar in the Indian market, Dr Himanshu Gadgil, CEO, Enzene Biosciences added, “Enzene Biosciences reaffirms its dedication to providing reliable and affordable medicines with the introduction of our ranibizumab biosimilar. As a people-focused company, we recognize human capital as our most valuable asset. Prior to ranibizumab, our teams have successfully delivered six commercial biosimilars and supported our partners with clinical supplies of novel biologic entities (NBE’s), such as monoclonal antibodies (mAbs) and multi-specific molecules. Additionally, we’ve pioneered the EnzeneX platform, a leading commercial continuous manufacturing platform. The successful commercialization of ranibizumab, a recombinant Fab, stands as a testament to the exceptional skills of our technical teams.”

Enzene Biosciences has taken another step toward becoming a worldwide known biosimilar firm, with an unrivaled track record of developing and delivering novel biosimilars in record time. Enzene's Chakan fill finish facility employs automated robotic arms that aid in the filling of these biosimilar pharmaceuticals into pre-sterile ready-to-use vials with minimum manual involvement, resulting in enhanced process controls and consistently high quality standards.